Initial antiretroviral therapy in chronically-infected HIV-positive adults.
Currently, there are 20 individual antiretroviral drugs and two co-formulation products that are approved by the FDA for the treatment of HIV-infected individuals. It is widely accepted that the selection of an appropriate first-line regimen is critical in assuring durable treatment response. This article reviews the factors that should be considered in the selection of an initial antiretroviral regimen and present the currently available evidence regarding the status of individual antiretroviral agents and treatment strategies relative to these factors.
Temesgen
Zelalem
Z
Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, MN 55905, USA. temesgen.zalalem@mayo.edu
Cainelli
Francesca
F
Warnke
David
D
Koirala
Janak
J
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D004357:Drug Synergism; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D016896:Treatment Outcome
D019380:Anti-HIV Agents